Phablo.ai
Category: AI in Healthcare
AI-native compliance engine that automates regulatory workflows for life sciences companies Phablo.ai was founded in 2025. The company is led by Marc Gerlach. Based in Singapore. Team size: 3. Total funding raised: $125,000. Latest round: Pre-Seed. Key investors include Antler.
- Founded
- 2025
- Headquarters
- Singapore
- Team size
- 3
- Total funding
- $125,000
Value proposition
Automates the creation of compliance documents, significantly reducing time and cost associated with regulatory submissions, accelerating go-to-market timeline for life sciences products
Products and solutions
AI-powered platform for automating regulatory documentation, Workflow automation for compliance processes, Solutions for managing and responding to regulatory queries
Unique value
AI-native compliance engine built from day one (not patched), specifically designed for life sciences regulatory workflows with focus on 'Day 120' query responses
Target customer
Pharmaceutical, biotechnology, and medical device companies
Industries served
Life Sciences, Pharmaceuticals, Biotechnology, Medical Devices
Technology advantage
AI can interpret complex regulatory guidelines and generate compliant documentation, offering significant speed and efficiency improvements over manual methods. Combines AI platform with expert support as one-stop solution
How they differentiate
Offers a combined tech-and-expert model (AI platform plus expert support) as a one-stop solution for compliance needs, differentiating from traditional consultants and pure SaaS providers
Main competitors
Scrut Automation, Sprinto
Key partnerships
Antler (Pre-seed investor and accelerator)
Major milestones
Secured $125,000 in pre-seed funding from Antler, Development and launch of AI-powered compliance automation platform, Plans to onboard first 100 paying customers over next two years
Growth metrics
$330K revenue in 2025 with 3-person team
Market positioning
Positioned as a B2B SaaS platform specializing in compliance automation for life sciences companies, helping them navigate evolving regulatory landscapes
Geographic focus
Primarily Singapore and India initially, with plans to expand to EU and US markets
Patents and IP
No publicly available patents at this stage
About Marc Gerlach
German co-founder with experience in international business, medtech, pharma, and global trade. Provides global perspective on cross-cultural collaboration and international markets.
Official website: https://phablo.ai/